John Treace Buys 22,887 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCI) CEO John Treace bought 22,887 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $4.04 per share, with a total value of $92,463.48. Following the transaction, the chief executive officer directly owned 7,376,150 shares of the company’s stock, valued at approximately $29,799,646. This trade represents a 0.31% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Treace Medical Concepts Price Performance

Shares of NASDAQ:TMCI opened at $4.06 on Friday. The company has a quick ratio of 2.53, a current ratio of 3.58 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $263.37 million, a PE ratio of -4.19 and a beta of 1.40. Treace Medical Concepts, Inc. has a twelve month low of $1.17 and a twelve month high of $7.78. The company has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $2.30.

Treace Medical Concepts (NASDAQ:TMCI) last issued its earnings results on Friday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. The firm had revenue of $47.20 million during the quarter, compared to analyst estimates of $45.96 million. Treace Medical Concepts had a negative net margin of 29.44% and a negative return on equity of 67.04%. Equities analysts forecast that Treace Medical Concepts, Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Monday, April 20th. Wall Street Zen raised shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Finally, Lake Street Capital lowered their price target on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $4.77.

Institutional Investors Weigh In On Treace Medical Concepts

Institutional investors and hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. purchased a new stake in shares of Treace Medical Concepts in the third quarter worth about $122,199,000. Weber Capital Management LLC ADV purchased a new stake in Treace Medical Concepts in the fourth quarter valued at approximately $1,445,000. William Blair Investment Management LLC raised its stake in Treace Medical Concepts by 17.2% in the third quarter. William Blair Investment Management LLC now owns 3,634,381 shares of the company’s stock valued at $24,387,000 after purchasing an additional 534,486 shares in the last quarter. First Eagle Investment Management LLC raised its stake in Treace Medical Concepts by 36.4% in the third quarter. First Eagle Investment Management LLC now owns 1,238,895 shares of the company’s stock valued at $8,313,000 after purchasing an additional 330,866 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in Treace Medical Concepts by 212.5% in the fourth quarter. GSA Capital Partners LLP now owns 347,755 shares of the company’s stock valued at $852,000 after purchasing an additional 236,477 shares in the last quarter. 84.08% of the stock is owned by hedge funds and other institutional investors.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.